CN1163272C - Tnf拮抗剂作为用于治疗脓毒性疾病的药物的用途 - Google Patents
Tnf拮抗剂作为用于治疗脓毒性疾病的药物的用途 Download PDFInfo
- Publication number
- CN1163272C CN1163272C CNB988105144A CN98810514A CN1163272C CN 1163272 C CN1163272 C CN 1163272C CN B988105144 A CNB988105144 A CN B988105144A CN 98810514 A CN98810514 A CN 98810514A CN 1163272 C CN1163272 C CN 1163272C
- Authority
- CN
- China
- Prior art keywords
- tnf
- serum levels
- tnf antagonist
- treatment
- time limit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 22
- 201000010099 disease Diseases 0.000 title claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 28
- 210000002966 serum Anatomy 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims description 5
- 230000000630 rising effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 27
- 229940100601 interleukin-6 Drugs 0.000 abstract description 25
- 238000005259 measurement Methods 0.000 abstract description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 38
- 102000003390 tumor necrosis factor Human genes 0.000 description 37
- 206010040047 Sepsis Diseases 0.000 description 15
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 229960003227 afelimomab Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19746868.3 | 1997-10-23 | ||
| DE19746868A DE19746868A1 (de) | 1997-10-23 | 1997-10-23 | Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1277556A CN1277556A (zh) | 2000-12-20 |
| CN1163272C true CN1163272C (zh) | 2004-08-25 |
Family
ID=7846420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988105144A Expired - Fee Related CN1163272C (zh) | 1997-10-23 | 1998-10-15 | Tnf拮抗剂作为用于治疗脓毒性疾病的药物的用途 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1024831A2 (fr) |
| JP (1) | JP2001521009A (fr) |
| KR (1) | KR20010024549A (fr) |
| CN (1) | CN1163272C (fr) |
| AU (1) | AU756167B2 (fr) |
| BR (1) | BR9813114A (fr) |
| CA (1) | CA2306790A1 (fr) |
| DE (1) | DE19746868A1 (fr) |
| HU (1) | HUP0100105A3 (fr) |
| IL (1) | IL135083A0 (fr) |
| NO (1) | NO20001894L (fr) |
| WO (1) | WO1999021582A2 (fr) |
| ZA (1) | ZA989615B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| UA76639C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| UA76640C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб |
| RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| US9308275B2 (en) | 2010-07-15 | 2016-04-12 | Oleg Iliich Epshtein | Method of increasing the effect of an activated-potentiated form of an antibody |
| PE20130397A1 (es) | 2010-07-15 | 2013-04-10 | Oleg Iliich Epshtein | Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal |
| EP2415461B1 (fr) * | 2010-07-24 | 2012-10-31 | Roche Diagnostics GmbH | Stabilisation d'interleukine 6 dans des solutions à base de sérum |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2638652B2 (ja) * | 1988-07-18 | 1997-08-06 | カイロン・コーポレーション | カケクチンと反応するモノクロナール抗体 |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
-
1997
- 1997-10-23 DE DE19746868A patent/DE19746868A1/de not_active Withdrawn
-
1998
- 1998-10-15 IL IL13508398A patent/IL135083A0/xx unknown
- 1998-10-15 KR KR1020007004361A patent/KR20010024549A/ko not_active Application Discontinuation
- 1998-10-15 CA CA002306790A patent/CA2306790A1/fr not_active Abandoned
- 1998-10-15 BR BR9813114-1A patent/BR9813114A/pt not_active IP Right Cessation
- 1998-10-15 EP EP98955459A patent/EP1024831A2/fr not_active Withdrawn
- 1998-10-15 AU AU12284/99A patent/AU756167B2/en not_active Withdrawn - After Issue
- 1998-10-15 JP JP2000517740A patent/JP2001521009A/ja active Pending
- 1998-10-15 CN CNB988105144A patent/CN1163272C/zh not_active Expired - Fee Related
- 1998-10-15 HU HU0100105A patent/HUP0100105A3/hu unknown
- 1998-10-15 WO PCT/EP1998/006545 patent/WO1999021582A2/fr not_active Application Discontinuation
- 1998-10-22 ZA ZA9809615A patent/ZA989615B/xx unknown
-
2000
- 2000-04-12 NO NO20001894A patent/NO20001894L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL135083A0 (en) | 2001-05-20 |
| EP1024831A2 (fr) | 2000-08-09 |
| JP2001521009A (ja) | 2001-11-06 |
| DE19746868A1 (de) | 1999-04-29 |
| CA2306790A1 (fr) | 1999-05-06 |
| BR9813114A (pt) | 2000-08-15 |
| NO20001894D0 (no) | 2000-04-12 |
| AU756167B2 (en) | 2003-01-09 |
| NO20001894L (no) | 2000-04-12 |
| CN1277556A (zh) | 2000-12-20 |
| HUP0100105A3 (en) | 2003-08-28 |
| ZA989615B (en) | 2000-04-20 |
| HUP0100105A2 (hu) | 2001-05-28 |
| AU1228499A (en) | 1999-05-17 |
| KR20010024549A (ko) | 2001-03-26 |
| WO1999021582A3 (fr) | 1999-07-15 |
| WO1999021582A2 (fr) | 1999-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6235281B1 (en) | Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
| US20030012786A1 (en) | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients | |
| US20030161828A1 (en) | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure | |
| US11207381B2 (en) | Cytokine receptor peptides, compositions thereof and methods thereof | |
| CN1163272C (zh) | Tnf拮抗剂作为用于治疗脓毒性疾病的药物的用途 | |
| CN1229113C (zh) | 用于治疗自身免疫性疾病的药物组合物 | |
| SG182191A1 (en) | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus | |
| KR100414505B1 (ko) | 높은혈청수준의인터류킨-6을갖는질환을치료하기위한약물로서의항-tnf항체의용도 | |
| MXPA00003355A (en) | Application of tnf antagonists as medicaments for treating septic diseases | |
| AU1549599A (en) | The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of the interleukin-6 | |
| AU5394001A (en) | The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
| Hong et al. | Level-Specific Differences in Systemic Expression of | |
| CZ20001407A3 (cs) | Použití TNF antagonistů pro výrobu drog k léčení septických poruch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |